TW201522378A - 用於治療人類癌症的特異性抗ｃｄ３８抗體 - Google Patents
用於治療人類癌症的特異性抗ｃｄ３８抗體 Download PDFInfo
- Publication number
- TW201522378A TW201522378A TW103137932A TW103137932A TW201522378A TW 201522378 A TW201522378 A TW 201522378A TW 103137932 A TW103137932 A TW 103137932A TW 103137932 A TW103137932 A TW 103137932A TW 201522378 A TW201522378 A TW 201522378A
- Authority
- TW
- Taiwan
- Prior art keywords
- antibody
- pharmaceutical composition
- dose
- administered
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361898309P | 2013-10-31 | 2013-10-31 | |
| EP14306220 | 2014-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201522378A true TW201522378A (zh) | 2015-06-16 |
Family
ID=51266255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103137932A TW201522378A (zh) | 2013-10-31 | 2014-10-31 | 用於治療人類癌症的特異性抗ｃｄ３８抗體 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20150118251A1 (enExample) |
| EP (2) | EP3063173B1 (enExample) |
| JP (3) | JP2016536314A (enExample) |
| KR (1) | KR20160077155A (enExample) |
| CN (1) | CN106103481A (enExample) |
| AU (1) | AU2014342103B2 (enExample) |
| BR (1) | BR112016009403A2 (enExample) |
| CA (1) | CA2927099A1 (enExample) |
| CR (1) | CR20160186A (enExample) |
| EA (1) | EA035098B1 (enExample) |
| IL (1) | IL245196B (enExample) |
| MA (2) | MA44560B2 (enExample) |
| MX (1) | MX373301B (enExample) |
| NZ (1) | NZ719784A (enExample) |
| PL (1) | PL3063173T3 (enExample) |
| PT (1) | PT3063173T (enExample) |
| SG (2) | SG10201803288RA (enExample) |
| TN (1) | TN2016000142A1 (enExample) |
| TW (1) | TW201522378A (enExample) |
| WO (1) | WO2015066450A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| SG10201913777XA (en) | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| WO2016040294A2 (en) | 2014-09-09 | 2016-03-17 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
| PE20171094A1 (es) | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
| US10533057B2 (en) * | 2015-05-13 | 2020-01-14 | Morphosys Ag | Treatment for multiple myeloma (MM) |
| CR20170526A (es) * | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| CN114656573B (zh) | 2015-05-30 | 2024-09-27 | 分子模板公司 | 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子 |
| WO2016201337A1 (en) * | 2015-06-12 | 2016-12-15 | Immungene, Inc. | Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| JP7027321B2 (ja) | 2015-11-03 | 2022-03-01 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体の皮下製剤及びその使用 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| CN108699161B (zh) | 2016-03-04 | 2022-06-03 | 莫佛塞斯公司 | 多发性骨髓瘤中m-蛋白应答的临床评估 |
| IL299221A (en) | 2016-06-21 | 2023-02-01 | Teneobio Inc | Cd3 binding antibodies |
| WO2018002181A1 (en) | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
| CR20220578A (es) | 2016-09-14 | 2023-01-17 | Teneobio Inc | Anticuerpos de unión a cd3 |
| EP3559035A1 (en) | 2016-12-21 | 2019-10-30 | TeneoBio, Inc. | Anti-bcma heavy chain-only antibodies |
| JP7240335B2 (ja) | 2017-06-20 | 2023-03-15 | テネオワン， インコーポレイテッド | 抗ｂｃｍａ重鎖のみ抗体 |
| CN110891971B (zh) | 2017-06-20 | 2024-01-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| JPWO2019031444A1 (ja) * | 2017-08-07 | 2020-08-27 | 国立大学法人九州大学 | 細胞集団における特異的結合物質の占有率を測定する方法 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| US20200207867A1 (en) * | 2017-09-13 | 2020-07-02 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| KR20200076732A (ko) | 2017-11-03 | 2020-06-29 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Cd38-지시된 키메라 항원 수용체 작제물 |
| MX2020007429A (es) | 2018-01-12 | 2020-10-15 | Takeda Pharmaceuticals Co | Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38). |
| CA3095086A1 (en) * | 2018-03-28 | 2019-10-03 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| BR112021000065A2 (pt) | 2018-07-10 | 2021-04-06 | Sanofi | Terapias de combinação contra câncer direcionando cd38 e tgf-beta |
| MX2021007047A (es) | 2018-12-14 | 2021-10-26 | Morphosys Ag | Formulaciones de anticuerpos. |
| JP2022525928A (ja) * | 2019-03-21 | 2022-05-20 | ガミダ セル リミテッド | 併用療法における移植に適したｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用 |
| CA3133654A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技（成都）有限公司 | 药物组合物及其制备方法和应用 |
| AU2020397170A1 (en) | 2019-12-05 | 2022-07-21 | Sanofi-Aventis U.S. Llc | Formulations of anti-CD38 antibodies for subcutaneous administration |
| TWI887310B (zh) * | 2019-12-06 | 2025-06-21 | 美商賽諾菲 安萬特美國有限責任公司 | 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途 |
| WO2021259227A1 (zh) * | 2020-06-23 | 2021-12-30 | 江苏康缘药业股份有限公司 | 抗cd38抗体及其用途 |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| US20250382378A1 (en) * | 2022-10-31 | 2025-12-18 | Genmab A/S | Cd38 antibodies and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CN1976950B (zh) * | 2004-02-06 | 2012-08-29 | 莫佛塞斯公司 | 抗cd38人抗体及其用途 |
| EP2551282A3 (en) | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| TW200745162A (en) * | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| PL2081595T3 (pl) * | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2191841A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191842A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191843A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CN104203982B (zh) * | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| SG10201913777XA (en) * | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
-
2014
- 2014-10-31 MX MX2016005666A patent/MX373301B/es active IP Right Grant
- 2014-10-31 PL PL14799089T patent/PL3063173T3/pl unknown
- 2014-10-31 TN TN2016000142A patent/TN2016000142A1/en unknown
- 2014-10-31 PT PT147990899T patent/PT3063173T/pt unknown
- 2014-10-31 CN CN201480071448.0A patent/CN106103481A/zh active Pending
- 2014-10-31 SG SG10201803288RA patent/SG10201803288RA/en unknown
- 2014-10-31 BR BR112016009403A patent/BR112016009403A2/pt not_active Application Discontinuation
- 2014-10-31 MA MA44560A patent/MA44560B2/fr unknown
- 2014-10-31 TW TW103137932A patent/TW201522378A/zh unknown
- 2014-10-31 CA CA2927099A patent/CA2927099A1/en not_active Abandoned
- 2014-10-31 NZ NZ719784A patent/NZ719784A/en unknown
- 2014-10-31 KR KR1020167013974A patent/KR20160077155A/ko not_active Ceased
- 2014-10-31 JP JP2016527374A patent/JP2016536314A/ja active Pending
- 2014-10-31 WO PCT/US2014/063380 patent/WO2015066450A1/en not_active Ceased
- 2014-10-31 US US14/529,719 patent/US20150118251A1/en not_active Abandoned
- 2014-10-31 MA MA39070A patent/MA39070A1/fr unknown
- 2014-10-31 EA EA201690905A patent/EA035098B1/ru not_active IP Right Cessation
- 2014-10-31 AU AU2014342103A patent/AU2014342103B2/en active Active
- 2014-10-31 EP EP14799089.9A patent/EP3063173B1/en active Active
- 2014-10-31 EP EP20188077.0A patent/EP3805266A1/en not_active Withdrawn
- 2014-10-31 SG SG11201603088RA patent/SG11201603088RA/en unknown
-
2016
- 2016-04-19 IL IL245196A patent/IL245196B/en active IP Right Grant
- 2016-04-21 CR CR20160186A patent/CR20160186A/es unknown
-
2017
- 2017-04-05 US US15/479,500 patent/US20180022814A1/en not_active Abandoned
-
2023
- 2023-05-24 JP JP2023085105A patent/JP2023109927A/ja active Pending
-
2025
- 2025-05-07 JP JP2025077126A patent/JP2025139586A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201603088RA (en) | 2016-05-30 |
| AU2014342103B2 (en) | 2020-06-04 |
| JP2023109927A (ja) | 2023-08-08 |
| PL3063173T3 (pl) | 2021-01-11 |
| CA2927099A1 (en) | 2015-05-07 |
| PT3063173T (pt) | 2020-10-20 |
| MA44560A1 (fr) | 2019-09-30 |
| EP3805266A1 (en) | 2021-04-14 |
| MA44560B2 (fr) | 2021-01-29 |
| EA035098B1 (ru) | 2020-04-27 |
| MX2016005666A (es) | 2016-07-14 |
| AU2014342103A1 (en) | 2016-05-26 |
| TN2016000142A1 (en) | 2017-10-06 |
| CN106103481A (zh) | 2016-11-09 |
| US20150118251A1 (en) | 2015-04-30 |
| BR112016009403A2 (pt) | 2017-09-19 |
| SG10201803288RA (en) | 2018-05-30 |
| IL245196B (en) | 2021-04-29 |
| EA201690905A1 (ru) | 2016-08-31 |
| MA39070A1 (fr) | 2017-11-30 |
| US20180022814A1 (en) | 2018-01-25 |
| JP2025139586A (ja) | 2025-09-26 |
| EP3063173A1 (en) | 2016-09-07 |
| WO2015066450A1 (en) | 2015-05-07 |
| MX373301B (es) | 2020-04-24 |
| NZ719784A (en) | 2022-02-25 |
| JP2016536314A (ja) | 2016-11-24 |
| CR20160186A (es) | 2016-06-13 |
| KR20160077155A (ko) | 2016-07-01 |
| IL245196A0 (en) | 2016-06-30 |
| MA44560B1 (fr) | 2020-06-30 |
| EP3063173B1 (en) | 2020-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023109927A (ja) | ヒトのがんを治療するための特異的抗ｃｄ３８抗体 | |
| US12121579B2 (en) | Antibodies specific to human t-cell immunoglobulin and ITIM domain (TIGIT) | |
| JP6914283B2 (ja) | ヒトのがんを治療するための特異的抗ｃｄ３８抗体 | |
| TW202440636A (zh) | Ｃｄ１９／ｃｄ３８多特異性抗體 | |
| TW201916890A (zh) | 抗ｐｄ－１抗體和抗ｌａｇ－３抗體聯合在製備治療腫瘤的藥物中的用途 | |
| CN108513615A (zh) | 结合人大麻素1(cb1)受体的抗体 | |
| US20240270840A1 (en) | Antibodies against cd112r and uses thereof | |
| TW202504915A (zh) | 以抗ｃｄ３及ｃｄ２０之雙特異性抗體治療淋巴瘤之方法 | |
| US20230406936A1 (en) | Anti-pd-l1 antibody and use thereof | |
| TW202428608A (zh) | 抗b7h3抗體以及其使用方法 | |
| TW202345895A (zh) | 在用於治療瀰漫性大型ｂ細胞淋巴瘤之組合療法中針對ｃｄ３和ｃｄ２０之雙特異性抗體 | |
| TW202346366A (zh) | 標靶ｐｄ－ｌ１和ｃｄ４０的抗原結合蛋白及其製備和應用 | |
| CN113368232B (zh) | 多特异性抗原结合蛋白及其应用 | |
| WO2026046327A1 (en) | Cdh17 targetting antibodies, chimeric antigen receptors, and uses thereof | |
| JP7384668B2 (ja) | 細胞傷害性ｔ細胞枯渇用組成物 | |
| JP2025519552A (ja) | がんの治療のためのｓｉｒｐアルファ融合タンパク質及び抗ｃｄ１９抗体を含む併用療法 | |
| TW202430214A (zh) | Cd47阻斷劑及抗bcma/抗cd3雙特異性抗體之組合療法 | |
| CN119998319A (zh) | 针对ceacam5和cd47的双特异性抗体与针对ceacam5和cd3的双特异性抗体的组合治疗 | |
| HK1223116B (en) | Specific anti-cd38 antibodies for treating human cancers |